Beijing SL Pharmaceutical Co., Ltd.

The company is the first high-tech enterprise in the capital to land on the Shenzhen Stock Exchange. Since its establishment in 1994, the company has researched, developed and put on the market more than 70 varieties of Class 1 drugs, including 3 national-level new drugs with independent intellectual property rights, with technological advantages and continuous innovation. The company closely lays out product research and development around changes in the disease spectrum, and has rich product reserves in the fields of hematology, tumor treatment, cardiovascular and cerebrovascular treatment, liver disease treatment, diabetes treatment, and nephropathy treatment. The company mainly focuses on research, development, production and operation of genetic engineering and related drugs, and closely revolves around the changing layout of the disease spectrum in the field of R&D, production and service. The company's main products include tablets, hard capsules, granules, small-volume injections, freeze-dried powder injections, biochemical raw materials, therapeutic biological products, psychotropic drugs, medical toxic drugs, soft gels, nasal preparations, pills, aerosols, sprays, oral liquids, etc. The company has won the second prize of the National Science and Technology Progress Award and five awards of the Beijing Science and Technology Progress Award. It has applied independently as an enterprise four times and received funding from the National “863” Program Fund. Many projects have been funded by the National Technology Innovation Fund, and it is an industrialization base for the achievements of the four national “863” plans.